Detail akcie Staar Surgical online

Business Summary: STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Financial Summary: BRIEF: For the nine months ended 26 September 2025, STAAR Surgical Co revenues decreased 31% to $181.6M. Net loss totaled $62.1M vs. income of $14M. Revenues reflect ICLs segment decrease of 84% to $41.5M, China segment decrease of 60% to $61.5M, Others segment decrease of 11% to $58.2M. Net loss reflects Stock-based Compensation in SGA increase of 6% to $12.4M (expense), Stock-based Compensation in SGA increase of 9% to $4.1M (expense).